Endocrine Department, Dubai Hospital, United Arab Emirates.
Endocrine Department, Dubai Hospital, United Arab Emirates.
Diabetes Res Clin Pract. 2019 Apr;150:308-314. doi: 10.1016/j.diabres.2019.01.038. Epub 2019 Feb 13.
Most of Muslims patients with diabetes and Coronary Heart Disease (CHD) elect to fast in Ramadan, but the actual risk in this subset of patients with diabetes is largely unknown. We aimed to understand the safety of fasting in CHD patients with diabetes insisting on fasting Ramadan under optimal care. We also monitored the change in biophysical and biochemical parameters of these patients before and after Ramadan. We conducted this prospective study in a tertiary care hospital in Dubai during Ramadan 2016, (June 6th till July 5th).
21 Patients with T2DM with stable known CHD during the three months prior to study and insisted on fasting despite advice against it were recruited for the study. All patients received continuous glucose monitoring with free style libre monitoring device (FSL-CGM) during and outside Ramadan period. We recorded DM or CVD-related emergency visit or hospitalisation, change in BMI, systolic and diastolic BP, lipids profile, e-GFR, HBA1c, and frequency of hypoglycemia during Ramadan fasting and not -fasting period.
This is first study using CGM in CHD patients with diabetes who observe fast in Ramadan. Patients had a significantly higher incidence (3.2 ± 2.8 vs 1.1 ± 1.6 episodes, p = 0.033) and prolonged duration of hypoglycemia (117.8 ± 87.2, 49.1 ± 59.1 min p 0.022) during fasting compared to non-fasting respectively. No significant alteration was seen in BMI, SBP and DBP, lipid profile and renal function. There is a significant improvement in HBA1c during Ramadan.
We could not associate any adverse cardiovascular effects with fasting Ramadan in patients with stable CHD under optimal diabetes care. FSL-CGMS data showed higher frequency of hypoglycemia during Ramadan fasting. Studies with larger sample size are needed for further validation of these findings.
大多数患有糖尿病和冠心病 (CHD) 的穆斯林患者选择在斋月期间禁食,但糖尿病患者中这部分人群的实际风险在很大程度上尚不清楚。我们旨在了解在最佳护理下坚持在斋月禁食的 CHD 合并糖尿病患者禁食的安全性。我们还监测了这些患者在斋月前后生物物理和生化参数的变化。我们在 2016 年斋月期间(6 月 6 日至 7 月 5 日)在迪拜的一家三级保健医院进行了这项前瞻性研究。
21 例在研究前三个月内患有 T2DM 合并稳定已知 CHD 且尽管有反对意见仍坚持禁食的患者被招募入组。所有患者在斋月期间和斋月之外都使用 FreeStyle Libre 监测设备 (FSL-CGM) 进行连续血糖监测。我们记录了 DM 或 CVD 相关的急诊就诊或住院情况、体重指数、收缩压和舒张压、血脂谱、e-GFR、HBA1c 的变化,以及在斋月禁食和不禁食期间低血糖的发生频率。
这是第一项使用 CGM 监测在斋月期间禁食的 CHD 合并糖尿病患者的研究。患者的低血糖发生率(3.2±2.8 比 1.1±1.6 次,p=0.033)和持续时间(117.8±87.2 比 49.1±59.1 分钟,p=0.022)明显更高。体重指数、收缩压和舒张压、血脂谱和肾功能均无明显变化。HBA1c 在斋月期间有显著改善。
我们无法将任何不良心血管事件与在最佳糖尿病护理下稳定 CHD 患者的斋月禁食联系起来。FSL-CGMS 数据显示,在斋月禁食期间低血糖的发生频率更高。需要更大样本量的研究进一步验证这些发现。